Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BYMolecules (Basel, Switzerland)

Development of a Novel Nanoparticle Targeting Endothelial Cells from Patients with Pulmonary Arterial Hypertension

  • Gabriel Floarea1
  • Nasser Assi1
  • Maytham Ismail1
  • Anderson Gattis1
  • Tadanori Mammoto2,3
  • Akiko Mammoto2,4
  • Mathumai Kanapathipillai1
4 affiliations
  1. 1Department of Mechanical Engineering, University of Michigan-Dearborn, 4901 Evergreen Road, Dearborn, MI 48128, USA
  2. 2Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA
  3. 3Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
  4. 4Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226, USA
Read full textPDFDOICite

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease driven largely by oxidative stress and inflammation. The pulmonary arterial endothelium plays a key role in PAH pathogenesis. In this study, we developed novel poly(lactic-co-glycolic acid) (PLGA)-based lutein nanoparticles coated with a Vascular Cell Adhesion Molecule-1 (VCAM-1) antibody to target pulmonary arterial endothelial cells (PAECs) associated with PAH. Lutein, a potent antioxidant and anti-inflammatory carotenoid, served as the model drug. The lutein nanoparticles were produced by nanoprecipitation, followed by surface modification with VCAM-1 antibody. Physicochemical characterization and cellular efficacy studies were performed to assess the potential of the formulation. The studies revealed the production of nanoparticles with an average size of approximately 170 nm that exhibited specificity for PAH patient-derived PAECs (PAH-PAECs) and antioxidant and anti-inflammatory properties. Moreover, the nanoparticles did not exhibit significant cellular toxicity toward healthy PAECs. This proof-of-principle study demonstrates the therapeutic potential of targeted nanoparticles for the treatment of PAH.

Related

  1. Development of Versatile Nanoparticle System for Efficient Drug Delivery into Pulmonary Endothelium.
    Afzaal N Mohammed, Zicheng Deng, Arnab Misra +10
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textMaterials & polymersEurope PMC
  2. A dual-targeting lipid nanoparticle delivery system for precision phage therapy against multidrug-resistant Gram-negative bacteria
    Zhijun Chen, Wenjun Hu, Hui Nie +11
    Science AdvancesPeer-reviewedCC BY-NCFull textMaterials & polymersSci. Adv.CrossrefEurope PMCEurope PMC+1
  3. Shaping Tumor Targeting: How Nanoparticle Morphology Influences Penetration and Accumulation in 3D Breast Cancer Models
    Bonan Zhao, Michiel van Dijk, Anne van Gelder +7
    ChemRxivPreprintCC BYFull textMaterials & polymersChemRxiv
  4. Development of Novel Furan–Chalcone Derivatives as Targeting Bacterial DNA Gyrase and Topoisomerase IV: Design, Synthesis, and In Silico Studies
    Nagaraj N Durgadasheemi, Vishal CS
    Chemistry & biodiversityPeer-reviewedCC BY-NC-NDFull textOrganic chemistryEurope PMCPMC
  5. Nanotoxicology and Nanoparticle Safety in Biomedical Designs [Correction]
    International Journal of NanomedicinePeer-reviewedCC BY-NC 4.0Full textMaterials & polymersPMC

Cite

BibTeXRIS
BibTeX
@article{floarea2026development,
  title = {{Development of a Novel Nanoparticle Targeting Endothelial Cells from Patients with Pulmonary Arterial Hypertension}},
  author = {Gabriel Floarea and Nasser Assi and Maytham Ismail and Anderson Gattis and Tadanori Mammoto and Akiko Mammoto and Mathumai Kanapathipillai},
  journal = {Molecules (Basel, Switzerland)},
  year = {2026},
  month = oct,
  doi = {10.3390/molecules31193511},
  url = {https://europepmc.org/article/PMC/PMC13666496},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Development of a Novel Nanoparticle Targeting Endothelial Cells from Patients with Pulmonary Arterial Hypertension
AU  - Gabriel Floarea
AU  - Nasser Assi
AU  - Maytham Ismail
AU  - Anderson Gattis
AU  - Tadanori Mammoto
AU  - Akiko Mammoto
AU  - Mathumai Kanapathipillai
PY  - 2026
DA  - 2026/10/01
JO  - Molecules (Basel, Switzerland)
DO  - 10.3390/molecules31193511
UR  - https://europepmc.org/article/PMC/PMC13666496
AB  - Pulmonary arterial hypertension (PAH) is a devastating disease driven largely by oxidative stress and inflammation. The pulmonary arterial endothelium plays a key role in PAH pathogenesis. In this study, we developed novel poly(lactic-co-glycolic acid) (PLGA)-based lutein nanoparticles coated with a Vascular Cell Adhesion Molecule-1 (VCAM-1) antibody to target pulmonary arterial endothelial cells (PAECs) associated with PAH. Lutein, a potent antioxidant and anti-inflammatory carotenoid, served as the model drug. The lutein nanoparticles were produced by nanoprecipitation, followed by surface modification with VCAM-1 antibody. Physicochemical characterization and cellular efficacy studies were performed to assess the potential of the formulation. The studies revealed the production of nanoparticles with an average size of approximately 170 nm that exhibited specificity for PAH patient-derived PAECs (PAH-PAECs) and antioxidant and anti-inflammatory properties. Moreover, the nanoparticles did not exhibit significant cellular toxicity toward healthy PAECs. This proof-of-principle study demonstrates the therapeutic potential of targeted nanoparticles for the treatment of PAH.
SN  - 1420-3049
ER  -